TC
NRXP icon

TownSquare Capital’s NRX Pharmaceuticals NRXP Stock Holding History

TownSquare Capital’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,041
Closed -$30.8K – 1259
2025
Q1 		$30.8K Hold
15,041
– – ﹤0.01% 1669
2024
Q4 		$33.1K Hold
15,041
– – ﹤0.01% 1553
2024
Q3 		$25.4K Buy
+15,041
New +$30.3K ﹤0.01% 1478

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

TownSquare Capital's NRXP Position: Q2 2025 in Review

TownSquare Capital sold out of NRX Pharmaceuticals (NRXP) in Q2 2025, closing a stake of 15,041 shares — an estimated $30.8K sold.

TownSquare Capital first reported a position in NRXP in Q3 2024 and held it in 3 quarters. The position peaked at $33.1K in Q4 2024. 25 funds tracked by Wall St. Rank hold NRXP as of Q2 2025.

  • TownSquare Capital reported no remaining NRX Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • TownSquare Capital sold 15,041 NRX Pharmaceuticals shares in Q2 2025, an estimated $30.8K.
  • TownSquare Capital first reported a position in NRX Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • TownSquare Capital's NRX Pharmaceuticals position peaked at $33.1K in Q4 2024.
  • 25 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2025.

Based on TownSquare Capital's 13F filing for Q2 2025, filed 13 Aug 2025.